U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973005) titled 'A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants' on May 07.
Brief Summary: The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants.
Study Start Date: May 09
Study Type: INTERVENTIONAL
Condition:
Advanced Chronic Liver Disease
Healthy Participants
Intervention:
DRUG: AZD2389
Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered...